Press releases

29
Dec 2022
21:30 E.S.T.

Mayflower Bioventures Launches its First Spin-Out, Primera Therapeutics, in Strategic Collaboration with Cellectis to Develop a Gene Editing Platform to Treat Mitochondrial Diseases

Read more
28
Dec 2022
17:59 E.S.T.

Cellectis secures a €40 million credit facility from the European Investment Bank to support its Research, Development and Innovation activities

Read more
22
Dec 2022
21:30 E.S.T.

Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL

Read more
13
Dec 2022
12:30 E.S.T.

Cellectis Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML

Read more
1
Dec 2022
21:30 E.S.T.

Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022

Read more
10
Nov 2022
14:05 E.S.T.

Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022

Read more
10
Nov 2022
07:30 E.S.T.

Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Unveiling Efficient Multitool/Multiplex Gene Engineering combining TALEN® and TALE Base Editors (TALE-BE)

Read more
3
Nov 2022
20:05 E.S.T.

Cellectis to Showcase Clinical Data from AMELI-01 and Preclinical Data from UCARTCS1 at ASH 2022

Read more
3
Nov 2022
17:43 E.S.T.

Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2022

Read more
27
Oct 2022
20:30 E.S.T.

Cellectis to Report Third Quarter 2022 Financial Results

Read more

Press contacts

For more information on any story, or for press enquiries, get in touch with our communication team

CONTACT US